Press Release

Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche

Poseida to receive $110 million upfront, with overall potential deal value of up to $6 billion
August 5, 2022

San Diego – August 5, 2022 – Cooley advised Poseida Therapeutics, a clinical-stage biopharmaceutical company, on its strategic collaboration and license agreement with Roche. Lawyers Ken Krisko, Marya Postner, Bin Wang, Hajra Nashin and Brendan Haberle led the Cooley team advising Poseida. 

The agreement will leverage Poseida’s novel approach to cell therapy and Roche’s expertise in developing and commercializing therapies to transform cancer care, and is focused on advancing multiple existing and additional next-generation allogeneic chimeric antigen receptor (CAR)-T programs directed toward hematologic malignancies.

Under the agreement, Poseida will receive $110 million upfront on the effective date – and may receive up to $110 million in near-term milestones and other payments.

Additionally, Poseida is eligible to receive research, development, launch, and net sales milestones and other payments totaling up to $6 billion in aggregate value.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe, and a total workforce of 3,300.